- Home
- KUKE vs RPHM Comparison
KUKE vs RPHM Comparison
Compare KUKE & RPHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KUKE
- RPHM
- Stock Information
- Founded
- KUKE 2002
- RPHM 2014
- Country
- KUKE China
- RPHM United States
- Employees
- KUKE N/A
- RPHM N/A
- Industry
- KUKE Other Consumer Services
- RPHM Biotechnology: Pharmaceutical Preparations
- Sector
- KUKE Real Estate
- RPHM Health Care
- Exchange
- KUKE Nasdaq
- RPHM Nasdaq
- Market Cap
- KUKE 49.8M
- RPHM 47.5M
- IPO Year
- KUKE 2021
- RPHM 2021
- Fundamental
- Price
- KUKE $0.74
- RPHM $1.77
- Analyst Decision
- KUKE
- RPHM Hold
- Analyst Count
- KUKE 0
- RPHM 6
- Target Price
- KUKE N/A
- RPHM $2.26
- AVG Volume (30 Days)
- KUKE 462.3K
- RPHM 316.0K
- Earning Date
- KUKE 10-15-2024
- RPHM 11-11-2024
- Dividend Yield
- KUKE N/A
- RPHM N/A
- EPS Growth
- KUKE N/A
- RPHM N/A
- EPS
- KUKE N/A
- RPHM N/A
- Revenue
- KUKE $15,080,878.00
- RPHM N/A
- Revenue This Year
- KUKE N/A
- RPHM N/A
- Revenue Next Year
- KUKE N/A
- RPHM N/A
- P/E Ratio
- KUKE N/A
- RPHM N/A
- Revenue Growth
- KUKE N/A
- RPHM N/A
- 52 Week Low
- KUKE $0.48
- RPHM $0.98
- 52 Week High
- KUKE $4.07
- RPHM $9.21
- Technical
- Relative Strength Index (RSI)
- KUKE 39.08
- RPHM 62.53
- Support Level
- KUKE $0.70
- RPHM $1.61
- Resistance Level
- KUKE $0.85
- RPHM $1.75
- Average True Range (ATR)
- KUKE 0.10
- RPHM 0.12
- MACD
- KUKE 0.01
- RPHM 0.03
- Stochastic Oscillator
- KUKE 51.23
- RPHM 89.58
About KUKE Kuke Music Holding Limited each representing one
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.
About RPHM Reneo Pharmaceuticals Inc.
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.